advertisement
Grus F 20
Showing records 1 to 20 | Display all abstracts from Grus F73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Anders F
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407
72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol f
Lorenz K
Trials 2017; 18: 128
73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Teister J
Scientific reports 2017; 7: 6260
72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol f
Scheller Y
Trials 2017; 18: 128
73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Teister J
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407
73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Anders F
Scientific reports 2017; 7: 6260
73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Funke S
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407
72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol f
Bell K
Trials 2017; 18: 128
73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Beck S; Funke S
Scientific reports 2017; 7: 6260
72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol f
Grus F
Trials 2017; 18: 128
73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Pfeiffer N
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407
73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
von Pein H
Scientific reports 2017; 7: 6260
73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Grus F
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407
72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol f
Ponto KA
Trials 2017; 18: 128
73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Prokosch V
Scientific reports 2017; 7: 6260
72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol f
Bock F
Trials 2017; 18: 128
73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Solon T; Prokosch V
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407
72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol f
Cursiefen C
Trials 2017; 18: 128
73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Pfeiffer N; Grus F
Scientific reports 2017; 7: 6260
72660 A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol f
Flach J; Gehring M; Peto T; Silva R; Tal Y; Pfeiffer N
Trials 2017; 18: 128
